• 한국동물학회지
• /
• 제38권2호
• /
• pp.204-211
• /
• 1995

In an effort to develop a new therapeutic strategy for human gene therapy of solid ovarian tumor, we studied the expression of the p53 tumor suppressor Sene as well as regulatory subunits of cyclic AMP (cAMP)-dependent protein kinase in human ovarian carcinoma cells. Four cell lines (2774, Caov-3, SK-OV-3 and OVCAR-3) were selected for the analyses. The p53 transcript and protein were detected only in the 2774 cell line by Northern and Western Bnalysis. In the relatively fast growing cell line, SK-OV-3, the %rope 1 a regulstorv subunit (RIA of CAMP-dependent protein kinase was the highest among the four cell lines. The expression level of $RII\beta$ protein was low in the four cell lines examined. These results maw point to a direction to select the target gene(sl to be employed for gene therapy to control the ovarian cancer.

• 대한한방내과학회지
• /
• 제44권6호
• /
• pp.1346-1353
• /
• 2023

Objectives: This long-term case report presents the case of an ovarian cancer patient with brain, cervical lymph node, and vertebral metastasis suppressed by traditional Korean medicine in combination with cytokine-induced killer (CIK) cell-based immunotherapy. Methods: The patient received acupuncture, moxibustion, GunChil-go, Hangam-dan, and CIK cell-based immunotherapy. The Eastern Cooperative Oncology Group and tumor markers were used to evaluate the treatment effects. Results: Integrative cancer treatment suppressed the progression of cancer, and the patient achieved eight-year survival. The performance status improved, and the tumor marker level was maintained. Conclusions: We suggest that an integrative cancer treatment that includes traditional Korean medicine can be a meaningful treatment option for advanced ovarian cancer.

• 생명과학회지
• /
• 제27권1호
• /
• pp.1-7
• /
• 2017

비정상적 액틴의 재구성은 암세포의 대표적 특성이다. Thymosin ${\beta}_{10}$ (TB10)과 Profilin-1 (PFN-1)은 액틴중합조절에 필수적인 단백질이다. 이전의 연구에서 본 연구진은 TB10이 F-actin의 구조를 파괴하여 난소 암 세포의 사멸을 일으킨다는 사실을 보고하였으나 그 기전에 대하여 보고 된 바는 아직까지 없다. 본 연구에서는 TB10에 의하여 PFN-1의 발현이 조절되며, PFN-1의 난소 암 저해 유전자로서의 새로운 기능을 보고하였다. 우선 난소암세포주인 SKOV3 세포에서 TB10에 의하여 발현이 조절되는 단백질들을 전기영동법과 liquid chromatography-mass spectroscopy (LC-MS/MS) 방법을 통하여 분석하였다. 그 결과 PFN-1이 TB10에 의하여 발현이 급격히 증가되는 단백질로 동정되었으며, 이 PFN-1을 난소 암 세포주인 SKOV3에 과발현 시켰을 때 암세포의 증식과 이동을 저해하고 암세포 사멸을 유도하였다. 또한 이 결과는 PFN-1에 의하여 Erk 신호전달기전이 저해되고 부수적으로 Elk-1과 Egr-1의 발현이 저해 됨으로써 유도될 가능성을 보여준다. 결론적으로, PFN-1이 난소암세포의 성장과 이동을 저해함과 동시에 세포사멸을 일으키므로 난소 암 치료에 유용하게 이용될 가능성이 높다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권12호
• /
• pp.5247-5250
• /
• 2016

Objective: Endometriosis, one of the most common estrogen dependent gynecological disorders, can present as both benign and malignant disease. The prevalence of tumoral transformation is 0.7-1.6% and the most common tumors are clear cell and endometrioid carcinomas. Unfortunately, the pathogenesis of transformation is unknown. For this purpose, we examined molecular alterations in ovarian endometriosis and endometriosis-associated tumors. Methods: Using the data bank of Alzahra hospital pathology department and paraffin blocks from appropriate cases were identified. Sections were cut and stained for 3 markers: estrogen receptor, P53 and bcl2. Correlations between findings were investigated. Results: Nineteen cases of endometriosis-associated tumor and 19 cases of endometriosis were identified. Staining for bcl2 was documented in 14 of 19 (73.7%) of endometriosis-associated tumor cases and also 7 of 19 (36.8%) endometriosis cases (P=0.02). Only 3 of the 19 (15.8%) endometriosis-associated tumors exhibited positive staining for estrogen receptors, compared with 14 of 19 (73.7%) endometriosis cases (P<0.001). Positive staining for P53 was noted in 5 of 19 (31.6%) endometriosis-associated ovarian tumor samples but was absent in endometriosis samples (0%), (P =0.008). Conclusions: Endometriosis-associated tumors appear to be associated with overexpression of bcl2 and P53 and reduced expression of Estrogen receptor. These finding may help to diagnose tumoral transformation with a background of endometriosis.

• 대한두경부종양학회지
• /
• 제36권2호
• /
• pp.73-77
• /
• 2020

Ovarian cancer is common malignant disease with high mortality in the female. However, lymph node metastasis in the head and neck of ovarian cancer is very rare than in para-aortic, pelvic lymph node. A 49-year-old female patient came to our clinic with a left neck mass. After total thyroidectomy and left selective neck dissection for the cervical neck level II, III, IV, V, VI for ovarian cancer and thyroid cancer, she had already undergone chemotherapy (Paclitaxel+Carboplatin) 18 month ago. CT scan showed only lymph node enlargement in left neck level II. Positron emission tomography-computed tomography (PET-CT) revealed a hypermetabolic lesion in same area but no other hypermetabolic lesion, especially in the pelvic and abdominal cavity. Fine needle aspiration cytology revealed metastatic carcinoma. The serum level of CA-125 was elevated to 43.8U/mL, whereas other tumor markers (CA 19-9, CEA) were in the normal range. She underwent a revision of selective neck lymph node dissection for the cervical neck levels I, II, and III, and on the review of surgical pathology, metastatic carcinoma was suspected. Thus, we performed immunohistochemical staining for the tissue; as a result, it was finally diagnosed as metastatic ovarian cancer (positive for CK7, ER and PR, and negative for CK20). Adjuvant chemotherapy (Paclitaxel+Carboplatin) was planned on the tumor board, and the patient successfully received chemotherapy.

• Advances in pediatric surgery
• /
• 제1권2호
• /
• pp.115-121
• /
• 1995

We reviewed 45 cases of ovarian tumors treated at Seoul National University Children's Hospital from 1983 to 1993. Forty-five patients were operated upon for 52 ovarian tumors. The most common pathologic diagnosis was mature teratoma. The next were functional cyst, the tumors of epithelial cell origin, and those of stromal origin in order of frequency. Six patients(13%) had malignant tumor. There were one malignant teratoma, two dysgerminomas, one endodermal sinus tumor, and two granulosa cell tumors. Four cases were diagnosed as torsion of ovarian cyst preoperatively, and emergency exploratory laparotomy were performed. There were three cases of ovarian tumors associated with precocious puberty. The most widely used diagnostic tool was ultrasonography. In the treatment of these 45 patients, unilateral oophorectomy was done in 38 cases, unilateral oophorectomy with wedge resection of contralateral ovary was done in 5 cases, unilateral oophorectomy with contralateral simple cystectomy was done in one case and total abdominal hysterectomy with bilateral salpingooophorectomy was done in one case. Of the six cases of malignancy, five patients are alive 2 to 6 years after operation and one case was lost to be followed up.

• BMB Reports
• /
• 제56권6호
• /
• pp.347-352
• /
• 2023

The protein family of poly (ADP-ribose) polymerases (PARPs) is comprised of multifunctional nuclear enzymes. Several PARP inhibitors have been developed as new anticancer drugs to combat resistance to chemotherapy. Herein, we characterized PARP4 mRNA expression profiles in cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. PARP4 mRNA expression was significantly upregulated in cisplatin-resistant ovarian cancer cell lines, and this upregulation was associated with the hypomethylation of specific cytosine-phosphate-guanine (CpG) sites (cg18582260 and cg17117459) on its promoter. Reduced PARP4 expression was restored by treating cisplatin-sensitive cell lines with a demethylation agent, implicating the epigenetic regulation of PARP4 expression by promoter methylation. Depletion of PARP4 expression in cisplatin-resistant cell lines reduced cisplatin chemoresistance and promoted cisplatin-induced DNA fragmentation. The differential mRNA expression and DNA methylation status at specific PARP4 promoter CpG sites (cg18582260 and cg17117459) according to cisplatin responses, was further validated in primary ovarian tumor tissues. The results showed significantly increased PARP4 mRNA expressions and decreased DNA methylation levels at specific PARP4 promoter CpG sites (cg18582260 and cg17117459) in cisplatin-resistant patients. Additionally, the DNA methylation status at cg18582260 CpG sites in ovarian tumor tissues showed fairly clear discrimination between cisplatin-resistant patients and cisplatin-sensitive patients, with high accuracy (area under the curve = 0.86, P = 0.003845). Our findings suggest that the DNA methylation status of PARP4 at the specific promoter site (cg18582260) may be a useful diagnostic biomarker for predicting the response to cisplatin in ovarian cancer patients.

• 대한세포병리학회지
• /
• 제1권2호
• /
• pp.121-128
• /
• 1990

자궁내막의 유두상 장액성 암종은 자궁 내막에서 발생하는 매우 희귀한 선암종의 한 형태로, 동명의 난소 암종과 조직학적으로 동일하며, 매우 불량한 예후를 나타낸다. 대개 이 종양은 말기에 진단되며, 같은 조직학적 소견을 보이는 전이성 난소암종과 혼돈되기 쉽다. 최근, 저자들은 자궁경부-질 도말 표본에서 2예의 유두상 장액성 암종을 진단 하였는데, 그 세포학적 소견은 종양 세포의 유두상 구조가 풍부하게 도말되었고, 종양 세포들은 거대한 핵소체를 가지고 있었다. 도말배경은 괴사성 및 혈성으로 종양소인을 잘 반영하고 있었다. 이 세포학적 진단은 자궁 절제 표본의 조직학적 검사로 확인 되었다.

• Journal of Yeungnam Medical Science
• /
• 제10권2호
• /
• pp.417-422
• /
• 1993

영남대학교 의과대학 부속병원에서 난소 악성 생식세포종으로 확진된 12례를 대상으로 CT 소견을 분석하여 다음과 같은 결론을 얻었다. 내배엽동 종양은 낭성 종괴내 일부 고형조직과 격막이 혼재되어 있는데 반하여 미성숙 기형종은 비교적 특징적인 지방조직과 석회화가 보였고, 미분화 세포종은 비록 1례지만 전형적인 낭성 종괴가 없는 고형 조직으로 충만하였다. 그러나 혼합 생식 세포종은 2종이상의 생식 세포종이 혼합된 종양이므로 특징적인 CT 소견없이 혼합된 종양들의 종류에 따라 다양하게 나타날 것으로 생각되었다. 또한 모든 종양들의 크기는 11cm에서 33cm의 비교적 컸다. 결론적으로 젊은 여성에서 큰 난소 종양이 있을 때 CT 영상에서 그 조직성상을 분석하면 그들의 감별진단이 가능하리라고 생각되었다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권15호
• /
• pp.6071-6074
• /
• 2014

Background: Evidence suggests that the rs11615 (C>T) polymorphism in the ERCC1 gene may be a risk factor for gynecological tumors. However, results have not been consistent. Therefore we performed this meta-analysis. Methods: Eligible studies were identified by search of PubMed, MEDLINE and Chinese National Knowledge Infrastructure (CNKI). Odds ratios (ORs) and 95% confidence intervals (CIs) were applied to assess associations between rs11615 (C>T) and gynecological tumor risk. Heterogeneity among studies was tested and sensitivity analysis was applied. Results: A total of 6 studies were identified, with 1,766 cases and 2,073 controls. No significant association was found overall between rs11615 (C>T) polymorphism and gynecological tumors susceptibility in any genetic model. In further analysis stratified by cancer type, significantly elevated ovarian cancer risk was observed in the homozygote and recessive model comparison (TT vs. CC: OR=1.69, 95% CI=1.03-2.77, heterogeneity=0.876; TT vs. CT/CC: OR=1.72, 95% CI=1.07-2.77, heterogeneity=0.995). Conclusion: The results of the present meta-analysis suggest that there is no significant association between the rs11615 (C>T) polymorphism and gynecological tumor risk, but it had a increased risk in ovarian cancer.